Objectives: To compare the prognosis of patients underwent radical resection for pancreatic ductal adenocarcinoma(PDAC) in Surveillance, Epidemiology, and End Results(SEER) and China Pancreas Data Center(CPDC), and to compare the prognostic factors for PDAC in both databases. Methods: The data of patients underwent radical resection for PDAC in CPDC database from January 2016 to December 2017 and SEER database from January 2014 to December 2015 were retrospectively analyzed. The prognosis of patients in both databases was analyzed by the Kaplan-Meier method, Log-rank method, and propensity score matching, and the Cox proportional hazard regression was used to analyze the independent prognosis factors for PDAC. Results: There were 1 977 cases and 2 220 cases of pancreatic cancer that underwent radical resection from CPDC and SEER, respectively. There were more male patients(60.90%,1 204/1 977) than female patients(39.10%,773/1 977) in CPDC, while nearly 1∶1 ratio(male:1 112 cases,female:1108)was observed between male and female in SEER(χ²=48.977,P<0.01). The proportion of patients under 45 years old was the smallest in both databases, and the age group with the most significant proportion was 60 to 74 years old. The ratio of patients over 75 years old in the SEER(24.28%,539/2 220) was higher than that of CPDC(7.89%,156/1 977)(χ²=202.090,P<0.01), while the proportion of patients between 45 and 59 years old in CPDC(33.69%,666/1 977) was higher than that in SEER(19.77%,439/2 220)(χ²=103.640,P<0.01). There were more pancreatic head cancers than body and tail cancers in both databases, and no statistical difference was found in tumor size between the two databases (W=2 181 502,P=0.740). More positive and examined lymph nodes were found in SEER patients (W=3 265 131,W=2 954 363,all P<0.01); and the proportion of patients who had at least 15 lymph nodes dissected was higher in SEER(63.24%,1 404/2 220)(χ²=532.130,P<0.01). There were more patients without neoadjuvant or adjuvant therapy in CPDC(57.16%,1 130/1 977) than that in SEER(24.91%,553/2 220)(χ²=451.390,P<0.01). After propensity score matching, the overall survival for CPDC was better than that for SEER(Log-rank test:χ²=4.500,P=0.034), and the median overall survival was 24 months and 23 months respectively. Cox regressional analysis showed the common independent prognosis factors in both databases were ≥75 years old, pancreatic head cancer, poorly differentiated and undifferentiated tumors, T stage, N stage(All P<0.05). Neoadjuvant or adjuvant therapy was a protective factor in both databases(CPDC:Wald=27.082;SEER:Wald=212.285, all P<0.01) and 45 to 59 years old was protective factor in the SEER database(Wald=5.212,P=0.020). Conclusions: The data in both databases have a good consistency. However, in terms of data quality, examined lymph nodes count, and neoadjuvant/adjuvant therapy rate, the CPDC differs greatly from the SEER.
目的： 比较中国胰腺疾病大数据中心（CPDC）及SEER数据库中胰腺癌术后患者的预后及其影响因素。 方法： 回顾性分析CPDC 2016年1月至2017年12月、SEER数据库2014年1月至2015年12月收录的胰腺癌根治术后患者的临床资料。通过Kaplan-Meier、Log-rank、倾向性评分匹配等方法比较两个数据库患者的预后差异，通过Cox比例风险回归模型分析影响预后的因素。 结果： 由CPDC和SEER数据库中分别提取1 977例和2 220例接受根治性手术的胰腺癌患者资料。CPDC中男性比例（60.90%，1 204/1 977）高于女性（39.10%，773/1 977），而SEER数据库中男女比例约为1∶1（男性1 112例，女性1 108例）（χ²=48.977，P<0.01）。两个数据库中45岁以下的胰腺癌患者比例均较小，占比最大的年龄段均为60~74岁，SEER数据库中≥75岁患者比例（24.28%，539/2 220）高于CPDC（7.89%，156/1 977） （χ²=202.090，P<0.01）；CPDC中45~59岁胰腺癌患者比例（33.69%，666/1 977）高于SEER数据库（19.77%，439/2 220）（χ²=103.640，P<0.01）。两个数据库中胰头癌患者比例均大于胰体尾癌，且肿瘤最大径差异无统计学意义（W=2 181 502，P=0.740）。SEER患者的淋巴结清扫数目及转移淋巴结数目均多于CPDC（W=3 265 131、2 954 363，P值均<0.01）；SEER中淋巴结清扫数目≥15枚的患者比例（63.24%，1 404/2 220）高于CPDC（27.62%，546/1 977）（χ²=532.130，P<0.01）。CPDC中未接受辅助/新辅助治疗患者的比例（57.16%，1 130/1 977）高于SEER数据库（24.91%，553/2 220）（χ²=451.390，P<0.01）。经倾向性评分匹配后，CPDC和SEER数据库中患者的中位生存期分别为24个月和23个月（Log-rank检验：χ²=4.500，P=0.034）。Cox回归分析结果显示，两个数据库共同的独立预后因素包括：年龄≥75岁、胰头癌、低分化与未分化癌、T分期、N分期等（P值均<0.05）。两个数据库中新辅助或辅助治疗均为预后的保护性因素（CPDC：Wald=27.082；SEER：Wald=212.285，P值均<0.01），SEER数据库中年龄45~59岁为保护性因素（Wald=5.212，P=0.020）。 结论： 两个数据库具有较好的一致性；两个数据库中的资料在数据质量、淋巴结清扫数目、新辅助或辅助治疗率等方面存在差距。.